US Pharma MarketingDiabetes cell therapy biotechs Sernova and Seraxis to merge
Sernova and Seraxis to merge into BetaNova Biotherapeutics, combining islet cell programs in the same realm as Vertex and CRISPR Therapeutics. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for…
Two companies that have spent decades trying to develop cell therapies for diabetes are set to merge, with the aim of working together to take on a market also being pursued by Vertex and CRISPR ...
Source: Endpoints News